The litigation centers on a volatile period for the digital healthcare platform, beginning in November 2025. Despite initial reports of strong quarterly results, Doximity signaled caution regarding advertising expenditures, causing shares to plummet 13.25% by November 7, 2025. This downward trend intensified on February 5, 2026, when the company slashed its full-year revenue guidance and reported contracting net income, driving the stock down another 16.78% the following day.
In section Releases
Investors Face November Deadline in Doximity Securities Class Action
Investors who suffered losses in Doximity, Inc. are facing a November 16, 2026, deadline to seek status as lead plaintiffs in a class action lawsuit. Pomerantz LLP alleges the company engaged in securities fraud, following a series of stock price drops triggered by missed revenue targets and decelerated growth.
Further pressure mounted on May 13, 2026, when Doximity missed its revised revenue projections and forecasted a slower growth trajectory for fiscal year 2027. The ensuing 23% single-day stock decline prompted multiple analyst downgrades. Pomerantz LLP is now representing shareholders who acquired stock during the period, alleging that company officers and directors misled investors regarding business practices. Those wishing to participate in the action or seeking additional information can contact Danielle Peyton at 646-581-9980 or visit the firm’s website.
Comments (0)
No comments yet. Be the first!